TVARDI THERAPEUTICS INC (TVRD) Forecast, Price Target & Analyst Ratings
NASDAQ:TVRD • US1407553072
3.93 USD
-0.09 (-2.24%)
At close: Mar 6, 2026
3.93 USD
0 (0%)
After Hours: 3/6/2026, 8:00:02 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for TVARDI THERAPEUTICS INC (TVRD).
Forecast Snapshot
Consensus Price Target
$15.15
+ 285.60% Upside
Next Earnings Forecast
Release DateMar 9, 2026
PeriodQ4 / 2025
EPS Estimate-$0.66
Revenue Estimate
ChartMill Buy Consensus
77.14%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$15.15
Upside
+ 285.60%
From current price of $3.93 to mean target of $15.15, Based on 14 analyst forecasts
Low
$4.04
Median
$10.20
High
$54.60
Price Target Revisions
1 Month
0.00%
3 Months
-24.64%
Price Target Summary
14 analysts have analysed TVRD and the average price target is 15.15 USD. This implies a price increase of 285.6% is expected in the next year compared to the current price of 3.93.
The average price target has been revised downward by 24.64% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
77.14%
TVRD was analyzed by 14 analysts. The buy percentage consensus is at 77. So analysts seem to be have mildly positive about TVRD.
In the previous month the buy percentage consensus was at a similar level.
TVRD was analyzed by 14 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-10-14 | Raymond James | Downgrade | Outperform -> Market Perform |
| 2025-10-13 | BTIG | Maintains | Buy -> Buy |
| 2025-10-13 | Barclays | Initiate | Overweight |
| 2025-07-14 | Raymond James | Initiate | Outperform |
| 2025-07-11 | Cantor Fitzgerald | Initiate | Overweight |
| 2025-06-12 | Piper Sandler | Initiate | Overweight |
| 2025-05-21 | Oppenheimer | Initiate | Outperform |
| 2025-04-28 | Jones Trading | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 9, 2026
PeriodQ4 / 2025
EPS Estimate-$0.66
Revenue Estimate
Revenue Q2Q-100.00%
EPS Q2Q-240.13%
Number of Analysts10
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
12.52%
Next Earnings Summary
TVRD is expected to report earnings on 3/9/2026. The consensus EPS estimate for the next earnings is -0.66 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 41.9M 82.17% | 20.968M -49.96% | 7.137M -65.96% | 331.5K -95.36% | -100.00% | 4.898M | 7.661M 56.41% | 28.307M 269.49% | 48.598M 71.68% | 71.452M 47.03% | |||
| EBITDA YoY % growth | -87.25M 1.80% | -121.236M -38.95% | -52.626M 56.59% | -28.56M 45.73% | -37.74M -32.14% | -49.98M -32.43% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -87.5M 1.80% | -121.495M -38.85% | -52.818M 56.53% | -26.185M 50.42% | -27.74M -5.94% | -40.524M -46.08% | -48.726M -20.24% | -54.552M -11.95% | -52.887M 3.05% | -44.167M 16.49% | -20.352M 53.92% | -1.815M 91.08% | |
| Operating Margin | -208.83% | -579.43% | -740.06% | -7,898.85% | N/A | N/A | N/A | -1,113.75% | -690.34% | -156.03% | -41.88% | -2.54% | |
| EPS YoY % growth | -57.24 8.09% | -78.48 -37.11% | N/A 98.33% | -2.50 -91.17% | -2.10 16.21% | -3.62 -72.72% | -3.04 16.13% | -2.07 31.83% | -1.57 24.30% | -2.64 -68.22% | -2.50 5.03% | -2.42 3.46% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.66 -240.13% | -0.65 79.66% | -0.56 43.90% | -0.51 14.25% | -0.55 17.06% |
| Revenue Q2Q % growth | -100.00% | -100.00% | |||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -6.076M -9.53% | -6.527M -173.56% | -6.837M 22.91% | -7.325M -23.36% | -8.099M -33.30% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-40.39%
EPS Next 5 Year
-9.61%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
-25.99%
Revenue Next 5 Year
0.01%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
12.96%
EBIT Next 5 Year
N/A
TVARDI THERAPEUTICS INC / TVRD Forecast FAQ
What is the price target for TVRD stock?
14 analysts have analysed TVRD and the average price target is 15.15 USD. This implies a price increase of 285.6% is expected in the next year compared to the current price of 3.93.
When does TVARDI THERAPEUTICS INC (TVRD) report earnings?
TVARDI THERAPEUTICS INC (TVRD) will report earnings on 2026-03-09, after the market close.
What are the consensus estimates for TVRD stock next earnings?
The consensus EPS estimate for the next earnings of TVARDI THERAPEUTICS INC (TVRD) is -0.66 USD and the consensus revenue estimate is 0 USD.
How do analysts rate TVARDI THERAPEUTICS INC (TVRD)?
The consensus rating for TVARDI THERAPEUTICS INC (TVRD) is 77.1429 / 100 . This indicates that analysts generally have a positive outlook on the stock.